血型鑑定试剂市场依产品类型、技术、样本类型和最终用户划分，全球预测（2026-2032年）

预计到 2025 年，血型鑑定试剂市场价值将达到 20.2 亿美元，到 2026 年将成长至 22.1 亿美元，到 2032 年将达到 41.5 亿美元，年复合成长率为 10.83%。

关键市场统计数据
基准年 2025	20.2亿美元
预计年份：2026年	22.1亿美元
预测年份 2032	41.5亿美元
复合年增长率 (%)	10.83%

对目前血型鑑定试剂状况的简要概述，涵盖技术趋势、供应状况和营运重点，为近期采购和研发决策提供资讯。

以下执行摘要概括了塑造现代血型鑑定试剂环境的关键背景、策略转折点和营运影响。它从实践观点概述了当前形势，旨在为采购、开发和临床应用方面的决策提供支援。读者将获得关于技术趋势、下游终端使用者需求、供应动态和竞争格局的简明分析，从而为即时的战术性选择和长期策略规划提供基础。

抗体工程、诊断平台和监管要求的创新如何重塑检查室工作流程、供应商伙伴关係和品质投资

血型鑑定试剂的市场格局正经历多重变革，这些变革正在改变检查室的工作流程和供应链关係。抗体工程和重组技术的进步正在重塑试剂的一致性和批间重复性，随着这些能力的扩展，它们正在影响血库、诊断检查室、医院和研究实验室的选择偏好。同时，诊断技术正从传统的手工凝集方法发展到整合流式细胞技术、微阵列和酶联免疫吸附检测法的平台，从而为更高通量和更丰富的数据采集创造了机会。

美国近期对试剂采购、供应连续性和筹资策略的关税累积影响，进一步凸显了多角化和在地采购的必要性。

美国近期关税政策的变化正在产生一系列累积效应，这些效应波及试剂采购、供应链韧性和成本管理策略。进口关税及相关贸易措施促使许多采购团队重新评估其供应商布局，并寻求建立多供应商结构以降低单一供应商风险。这种重新评估促使各组织尽可能优先选择本地供应商，加快对替代供应商的资质认证流程，并加强库存管理以减少交货中断。

从产品、技术、最终用户和样品类型等维度进行详细的細項分析，揭示了每个群体在检验、相容性和采购方面的差异。

详细的市场細項分析揭示了每种产品类型、技术、最终用户和样品基质的不同购买驱动因素和检验要求。在产品类型方面，市场由凝集素、单株抗体、多株抗体和重组抗体组成。单株抗体进一步分为融合瘤来源和重组形式，而多株抗体通常来自山羊或兔子。这些物质差异会影响批次稳定性、特异性光谱以及实验室必须管理的下游检验途径。

检验法规结构、实验室成熟度和分销策略在关键区域对采购、检验和支援模式的影响

区域趋势正在影响美洲、欧洲、中东和非洲以及亚太地区的需求模式、监管路径和筹资策略。在美洲，采购决策往往优先考虑快速反应、综合技术支援以及与区域监管指南的一致性。这促使试剂供应商与大型医院网路和血液服务提供者之间建立更紧密的伙伴关係，以确保及时交货和协调一致的检验计划。

竞争格局概述重点阐述检验的严格性、生产控制和综合支援计画如何为试剂供应商提供可持续的竞争优势

血型鑑定试剂市场的竞争动态呈现出多元化的态势，既有成熟的製造商，也有专注于试剂一致性、整合解决方案和服务品质的创新参与企业。现有企业通常拥有成熟的产品系列和广泛的分销网络，并利用与血库和医院系统建立的长期合作关係。同时，新参与企业则着重于重组抗体平台、先进的品管以及能够简化批次追踪和资料整合的数位化工具。

透过试剂工程和自动化，为领导企业提供提高供应链韧性、加快检验流程和降低营运风险的实用策略

产业领导者应采取一系列协调一致的行动，平衡供应链韧性、监管准备和技术差异化，以保障临床工作的连续性并创造未来机会。首先，应优先考虑供应商多元化和合格框架，以便在保持临床检验完整性的同时，快速引入替代製造商。建立预先核准的供应商层级和标准化的验收测试通讯协定，有助于在物流或贸易波动影响首选供应商时，减轻由此造成的干扰。

采用透明的混合方法，结合实务工作者访谈、技术评述和比较分析，得出可操作且可复製的研究结果。

本调查方法结合了结构化的初步研究、有针对性的二次研究以及严谨的分析综合，以确保获得可靠且可操作的洞见。初步数据透过与血库、诊断检查室、医院检查室和研究机构的专家进行访谈和讨论收集，以获得关于检验方法、采购标准和运营限制的第一手资讯。这些专家见解与产品文件、技术白皮书和监管指南进行交叉核对，以检验各类试剂的性能特征和品质预期。

本文简明扼要地总结了检查室和供应商在实现更稳健、更可重复的试剂操作方面应关注的策略重点和营运要务。

总之，受抗体工程技术的进步、诊断平台的不断发展以及监管要求的日益严格等因素驱动，血型鑑定试剂领域正处于一个转折点。这些因素正推动试剂形式和供应商关係转向更注重可重复性、文件记录和整合支援的模式。积极拓展供应商、强化检验框架并投资于数位化追溯的检查室和采购团队，将能够更好地管理营运风险并维持临床工作的连续性。

目录

第一章：序言

第二章调查方法

• 研究设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查前提
• 调查限制

第三章执行摘要

• 首席体验长观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会地图
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依产品类型分類的血型鑑定试剂市场

• 凝集素
• 单株抗体
  • 融合瘤衍生
  • 重组
• 多株抗体
  • 山羊
  • 兔子
• 重组抗体

第九章 依技术分類的血型鑑定试剂市场

• 凝血法
  • 直接团聚法
  • 间接团聚法
• 酵素免疫分析法
• 流式细胞技术
  • 萤光碱
  • 基于影像
• 微阵列

第十章 依检体类型分類的血型鑑定试剂市场

• 巴菲外套
• 电浆
• 血清
• 全血

第十一章 以最终用户分類的血型鑑定试剂市场

• 血库
• 诊断检查室
• 医院
• 研究所

第十二章 血型鑑定试剂市场（依地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章 血型鑑定试剂市场（依血型分类）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 各国血型鑑定试剂市场

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章：美国血型鑑定试剂市场

第十六章 中国血型鑑定试剂市场

第十七章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• Abbott Laboratories
• ARKRAY, Inc.
• Atlas Medical GmbH
• BAG Diagnostics GmbH
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Essange Reagents
• F. Hoffmann-La Roche Ltd
• Grifols, SA
• Immucor, Inc.
• Lorne Laboratories Limited
• Merck KGaA
• Meril Life Sciences Pvt. Ltd.
• Ortho Clinical Diagnostics Inc.
• Prestige Diagnostics
• QuidelOrtho Corporation
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Torax Biosciences Limited
• Tulip Diagnostics（P）Ltd.

The Blood Typing Reagent Market was valued at USD 2.02 billion in 2025 and is projected to grow to USD 2.21 billion in 2026, with a CAGR of 10.83%, reaching USD 4.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 2.02 billion
Estimated Year [2026]	USD 2.21 billion
Forecast Year [2032]	USD 4.15 billion
CAGR (%)	10.83%

A concise orientation to the blood typing reagent landscape that frames technology, supply dynamics, and operational priorities to inform immediate procurement and R&D decisions

The following executive summary synthesizes the essential context, strategic inflections, and operational implications shaping the contemporary blood typing reagent environment. It frames the current landscape through a practical lens that supports decisions across procurement, development, and clinical deployment. Readers will find concise analysis of technology trends, downstream end-user requirements, supply dynamics, and competitive positioning to aid immediate tactical choices as well as longer-term strategic planning.

This introduction highlights the convergence of advanced antibody engineering, automation in identification workflows, and evolving regulatory scrutiny that together redefine how laboratories and blood banks secure reagent reliability and reproducibility. As a result, stakeholders must reconcile legacy practices with an accelerating cadence of technological alternatives and materials sourcing options. The narrative that follows prioritizes clarity, actionable insight, and an evidence-backed view of how these forces interact in real-world settings, providing a foundation for the deeper sections that examine segmentation, regional dynamics, tariff impacts, and recommended actions.

How innovations in antibody engineering, diagnostic platforms, and regulatory expectations are reshaping laboratory workflows, supplier partnerships, and quality investments

The landscape for blood typing reagents is experiencing several transformative shifts that alter both laboratory workflows and supply chain relationships. Advances in antibody engineering and recombinant approaches are reshaping reagent consistency and batch-to-batch reproducibility, and as these capabilities scale, they influence preferences across blood banks, diagnostic laboratories, hospitals, and research institutions. Concurrently, diagnostic technologies are moving beyond classic manual agglutination to integrated platforms that combine flow cytometry, microarray, and enzyme-linked assays, creating opportunities for higher throughput and richer data capture.

Parallel to technological evolution, regulatory agencies are intensifying scrutiny on reagent validation, traceability, and clinical performance documentation. This increased oversight drives greater investment in quality systems and in suppliers that can demonstrate robust manufacturing controls. At the same time, end users demand more integrated solutions that reduce hands-on time and improve result consistency, prompting vendors to bundle reagents with software and automated hardware. Collectively, these shifts are increasing the strategic importance of supplier partnerships, diversification of sourcing strategies, and investment in in-house technical capabilities to validate new reagent formats and platforms.

The cumulative effects of recent United States tariff measures on reagent sourcing, supply continuity, and procurement strategies that reinforce diversification and localization imperatives

Recent tariff policy developments in the United States have created a set of cumulative impacts that reverberate through reagent sourcing, supply chain resilience, and cost-management strategies. Import duties and related trade measures have prompted many procurement teams to reassess supplier footprints and to seek multi-sourced arrangements that reduce single-point exposure. This reassessment has led organizations to prioritize nearer-shore suppliers when possible, accelerate qualification timelines for alternative vendors, and expand inventory governance to mitigate delivery interruptions.

In response, some manufacturers have adjusted their production strategies, evolving toward localized manufacturing or strategic distribution partnerships to preserve market access and service levels. These shifts can lengthen lead times for qualification but improve longer-term stability. Diagnostics developers and clinical laboratories have also responded by intensifying supplier performance metrics, requiring more detailed batch documentation and enforcing stricter acceptance testing upon receipt. Additionally, procurement teams increasingly incorporate total landed cost considerations and contractual terms that address tariff variability and shared risk, while regulatory teams keep a close watch on documentation continuity where supplier changes intersect with product registration or clinical validation obligations.

Detailed segmentation analysis across product, technology, end user, and sample type axes that highlights validation, compatibility, and procurement differentiators for each cohort

A granular view of segmentation reveals distinct purchase drivers and validation requirements across product types, technologies, end users, and sample matrices. Within product type, the market encompasses lectins, monoclonal antibodies, polyclonal antibodies, and recombinant antibodies; monoclonal antibodies further differentiate into hybridoma-derived and recombinant formats, and polyclonal antibodies typically originate from goat or rabbit hosts. These material distinctions influence lot stability, specificity profiles, and downstream validation pathways that laboratories must manage.

Examining diagnostic modalities, the technology spectrum includes agglutination, enzyme-linked immunosorbent assays, flow cytometry, and microarray platforms; agglutination itself divides into direct and indirect approaches, while flow cytometry manifests through fluorescence-based and image-based implementations. Each technological class imposes unique performance expectations, instrumentation compatibility needs, and operator skill requirements, thereby affecting purchasing criteria and training investments.

End users show differentiated priorities: blood banks concentrate on throughput, compatibility assurance, and regulatory traceability; diagnostic laboratories emphasize analytical sensitivity, reproducibility, and integration with laboratory information systems; hospitals balance turnaround times and on-site support; and research institutions prioritize experimental flexibility and reagent provenance. Finally, sample type matters significantly, with buffy coat, plasma, serum, and whole blood presenting distinct handling constraints, anticoagulant considerations, and pre-analytical workflows. Understanding how these segmentation layers intersect enables more precise product positioning, validation roadmaps, and service models tailored to each user cohort.

An examination of how regional regulatory frameworks, laboratory maturity, and distribution strategies across major geographies affect sourcing, validation, and support models

Regional dynamics influence demand patterns, regulatory pathways, and sourcing strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, procurement decisions often prioritize responsiveness, integrated technical support, and alignment with regional regulatory guidance. This has encouraged the development of closer partnerships between reagent suppliers and large hospital networks and blood services to ensure timely deliveries and coordinated validation programs.

Across Europe, Middle East & Africa, regulatory harmonization efforts and diverse payer environments shape procurement practices, driving emphasis on compliance documentation, CE marking or equivalent pathways, and flexible distribution models that accommodate variable market access requirements. Strategic distribution agreements and regional manufacturing sites can facilitate faster response times and tailored regulatory support. In the Asia-Pacific region, a broad spectrum of laboratory maturity-from advanced centralized testing centers to decentralized hospital labs-creates parallel demand for both high-throughput automated platforms and cost-efficient, robust manual reagents. Consequently, suppliers often adopt dual strategies that combine premium product lines for reference centers with resilient, lower-complexity offerings for decentralized settings.

These regional distinctions affect supplier selection, validation timelines, and after-sales support structures. They also inform decisions about local partnerships, inventory strategies, and training programs required to ensure consistent reagent performance in diverse clinical contexts.

A competitive landscape overview emphasizing how validation rigor, manufacturing controls, and integrated support programs create durable advantages for reagent suppliers

Competitive dynamics in the blood typing reagent space reflect a mix of legacy manufacturers, specialty reagent developers, and innovative entrants that prioritize reagent consistency, integrated solutions, and service excellence. Established producers often leverage long-standing relationships with blood banks and hospital systems, offering proven product portfolios and broad distribution reach. Meanwhile, newer entrants emphasize recombinant antibody platforms, advanced quality controls, and digital tools that simplify lot tracking and data integration.

Across the supplier landscape, differentiation frequently arises from the ability to provide robust technical documentation, reliable batch-to-batch performance, and responsive technical support. Firms that invest in scalable manufacturing controls and transparent validation data tend to earn trust among diagnostic laboratories and hospital procurement teams. In addition, vendors that offer programmatic support for qualification-such as protocol templates, on-site training, and digital traceability-improve adoption rates and deepen customer relationships. Partnerships between reagent manufacturers and instrument vendors are also notable, as those alliances facilitate bundled solutions that reduce validation burdens and accelerate laboratory workflow integration.

Actionable strategies for leaders to strengthen supply resilience, accelerate validation, and capitalize on reagent engineering and automation to reduce operational risk

Industry leaders should pursue a coordinated set of actions that balance supply resilience, regulatory readiness, and technological differentiation to protect clinical continuity and unlock future opportunities. First, prioritize supplier diversification and qualification frameworks that allow rapid onboarding of alternative manufacturers while preserving clinical validation integrity. Establishing pre-approved vendor tiers and standardized acceptance testing protocols helps reduce disruption when logistics or trade measures impact preferred suppliers.

Second, invest in reagent provenance and digital traceability systems that link lot information to quality records, operator training logs, and instrument configurations. Such investments improve audit readiness and facilitate faster root-cause analysis when deviations occur. Third, accelerate adoption of recombinant and engineered antibody formats where appropriate, as these products can reduce variability and ease long-term supply planning. Simultaneously, partner closely with instrument providers to develop validated reagent-instrument packages that reduce laboratory validation workloads.

Finally, implement contractual terms that address tariff exposure, delivery windows, and shared risk arrangements with suppliers, while reinforcing robust inventory governance to balance stockholding costs against service level requirements. These measures collectively enhance operational resilience, reduce total validation overhead, and position organizations to respond quickly to technological and regulatory shifts.

A transparent mixed-methods approach combining practitioner interviews, technical review, and comparative synthesis to produce actionable and reproducible insights

The research methodology combines structured primary engagements, targeted secondary review, and rigorous analytical synthesis to ensure robust, actionable findings. Primary inputs were collected through interviews and discussions with practitioners across blood banks, diagnostic laboratories, hospital laboratories, and research institutions to capture firsthand perspectives on validation practices, procurement criteria, and operational constraints. These practitioner insights were triangulated with product documentation, technical white papers, and regulatory guidance to validate performance attributes and quality expectations across reagent classes.

Secondary analysis involved systematic review of technical literature, regulatory communications, and supplier manufacturing specifications to map the relationships between reagent type, technology platform, and end-user requirements. The synthesis stage applied comparative analysis to identify recurring adoption drivers, supplier differentiators, and regional nuances, while careful attention to methodological transparency ensured reproducibility of findings. Throughout, the approach emphasized practical relevance by focusing on operational implications rather than purely theoretical assessments, supporting decision-makers with clear, implementable recommendations grounded in empirical evidence.

A concise synthesis of strategic priorities and operational imperatives that guide laboratories and suppliers toward more resilient, reproducible reagent practices

In conclusion, the blood typing reagent domain is at an inflection point driven by advances in antibody engineering, evolving diagnostic platforms, and heightened regulatory expectations. These forces encourage a shift toward reagent formats and supplier relationships that prioritize reproducibility, documentation, and integrated support. Laboratories and procurement teams that proactively diversify suppliers, strengthen validation frameworks, and invest in digital traceability will better manage operational risk and preserve clinical continuity.

Moreover, regional realities and tariff dynamics require tailored strategies that reconcile local regulatory requirements with resilience-focused procurement policies. By aligning product selection with end-user workflows and sample-type constraints, organizations can reduce validation burdens and improve diagnostic reliability. The recommendations provided herein offer a strategic roadmap for navigating current pressures while positioning organizations to take advantage of technological improvements and supplier innovations that enhance performance and reduce variability over time.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Typing Reagent Market, by Product Type

• 8.1. Lectin
• 8.2. Monoclonal Antibody
  • 8.2.1. Hybridoma Derived
  • 8.2.2. Recombinant
• 8.3. Polyclonal Antibody
  • 8.3.1. Goat
  • 8.3.2. Rabbit
• 8.4. Recombinant Antibody

9. Blood Typing Reagent Market, by Technology

• 9.1. Agglutination
  • 9.1.1. Direct Agglutination
  • 9.1.2. Indirect Agglutination
• 9.2. Enzyme Linked Immunosorbent Assay
• 9.3. Flow Cytometry
  • 9.3.1. Fluorescence Based
  • 9.3.2. Image Based
• 9.4. Microarray

10. Blood Typing Reagent Market, by Sample Type

• 10.1. Buffy Coat
• 10.2. Plasma
• 10.3. Serum
• 10.4. Whole Blood

11. Blood Typing Reagent Market, by End User

• 11.1. Blood Banks
• 11.2. Diagnostic Laboratories
• 11.3. Hospitals
• 11.4. Research Institutions

12. Blood Typing Reagent Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Blood Typing Reagent Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Blood Typing Reagent Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Blood Typing Reagent Market

16. China Blood Typing Reagent Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Abbott Laboratories
• 17.6. ARKRAY, Inc.
• 17.7. Atlas Medical GmbH
• 17.8. BAG Diagnostics GmbH
• 17.9. Becton, Dickinson and Company
• 17.10. Bio-Rad Laboratories, Inc.
• 17.11. Danaher Corporation
• 17.12. Essange Reagents
• 17.13. F. Hoffmann-La Roche Ltd
• 17.14. Grifols, S.A.
• 17.15. Immucor, Inc.
• 17.16. Lorne Laboratories Limited
• 17.17. Merck KGaA
• 17.18. Meril Life Sciences Pvt. Ltd.
• 17.19. Ortho Clinical Diagnostics Inc.
• 17.20. Prestige Diagnostics
• 17.21. QuidelOrtho Corporation
• 17.22. Siemens Healthineers AG
• 17.23. Thermo Fisher Scientific Inc.
• 17.24. Torax Biosciences Limited
• 17.25. Tulip Diagnostics (P) Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL BLOOD TYPING REAGENT MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL BLOOD TYPING REAGENT MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 12. CHINA BLOOD TYPING REAGENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY LECTIN, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY LECTIN, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY LECTIN, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY HYBRIDOMA DERIVED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY HYBRIDOMA DERIVED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY HYBRIDOMA DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY GOAT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY GOAT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY GOAT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RABBIT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RABBIT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RABBIT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RECOMBINANT ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RECOMBINANT ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RECOMBINANT ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY DIRECT AGGLUTINATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY DIRECT AGGLUTINATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY DIRECT AGGLUTINATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY INDIRECT AGGLUTINATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY INDIRECT AGGLUTINATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY INDIRECT AGGLUTINATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY FLUORESCENCE BASED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY FLUORESCENCE BASED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY FLUORESCENCE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY IMAGE BASED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY IMAGE BASED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY IMAGE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY BUFFY COAT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY BUFFY COAT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY BUFFY COAT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 79. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 81. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 82. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 83. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 84. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 85. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 86. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 87. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 88. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 89. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 90. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 91. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 92. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 93. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 94. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 95. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 96. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 97. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 98. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 99. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 100. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 101. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 102. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 103. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 104. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 105. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 106. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 107. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 108. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 109. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 114. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 115. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 116. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 117. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 118. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 119. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 120. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 121. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 122. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 123. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 124. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 125. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 126. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 127. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 128. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 129. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 130. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 131. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 132. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 133. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 134. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 135. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 136. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 137. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 138. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 139. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 140. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 141. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 142. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 143. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 144. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 145. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 146. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 147. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 148. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 149. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 150. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 151. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 152. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 153. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 154. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 155. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 156. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 157. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 158. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 159. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 160. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 161. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 162. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 163. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 164. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 165. GCC BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 166. GCC BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 167. GCC BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 168. GCC BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 169. GCC BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 170. GCC BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 171. GCC BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 172. GCC BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 173. GCC BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 174. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 175. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 176. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 177. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 178. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 179. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 180. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 181. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 182. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 183. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 184. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 185. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 186. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 187. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 188. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 189. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 190. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 191. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 192. G7 BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 193. G7 BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 194. G7 BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 195. G7 BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 196. G7 BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 197. G7 BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 198. G7 BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 199. G7 BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 200. G7 BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 201. NATO BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 202. NATO BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 203. NATO BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 204. NATO BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 205. NATO BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 206. NATO BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 207. NATO BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 208. NATO BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 209. NATO BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 210. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 211. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 212. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 213. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 214. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 215. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 216. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 217. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 218. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 219. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 220. CHINA BLOOD TYPING REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 221. CHINA BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 222. CHINA BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 223. CHINA BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
• TABLE 224. CHINA BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 225. CHINA BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
• TABLE 226. CHINA BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
• TABLE 227. CHINA BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 228. CHINA BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)